Active Ingredient History
Milatuzumab is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Graft vs Host Disease (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Lupus Erythematosus, Cutaneous (Phase 1/Phase 2)
Lupus Erythematosus, Discoid (Phase 1/Phase 2)
Lupus Erythematosus, Systemic (Phase 1/Phase 2)
Lupus Nephritis (Phase 1/Phase 2)
Lupus Vasculitis, Central Nervous System (Phase 1/Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 1)
Plasmacytoma (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue